MA50537A - Composés deutérés utilisés comme immunomodulateurs - Google Patents

Composés deutérés utilisés comme immunomodulateurs

Info

Publication number
MA50537A
MA50537A MA050537A MA50537A MA50537A MA 50537 A MA50537 A MA 50537A MA 050537 A MA050537 A MA 050537A MA 50537 A MA50537 A MA 50537A MA 50537 A MA50537 A MA 50537A
Authority
MA
Morocco
Prior art keywords
immunomodulators
compounds used
deuterated compounds
deuterated
compounds
Prior art date
Application number
MA050537A
Other languages
English (en)
Inventor
Pingchen Fan
Rebecca M Lui
Venkat Reddy Mali
Rajinder Singh
Yibin Zeng
Penglie Zhang
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of MA50537A publication Critical patent/MA50537A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA050537A 2017-10-30 2018-10-29 Composés deutérés utilisés comme immunomodulateurs MA50537A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762578586P 2017-10-30 2017-10-30

Publications (1)

Publication Number Publication Date
MA50537A true MA50537A (fr) 2021-04-07

Family

ID=66333578

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050537A MA50537A (fr) 2017-10-30 2018-10-29 Composés deutérés utilisés comme immunomodulateurs

Country Status (11)

Country Link
US (2) US20190144389A1 (fr)
EP (1) EP3703687A4 (fr)
JP (1) JP2021501175A (fr)
KR (1) KR20200109298A (fr)
CN (1) CN111741754A (fr)
AU (1) AU2018359214A1 (fr)
CA (1) CA3077395A1 (fr)
IL (1) IL273605A (fr)
MA (1) MA50537A (fr)
TW (1) TW201922704A (fr)
WO (1) WO2019089468A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11542256B2 (en) 2017-09-03 2023-01-03 Angion Biomedica Corp. Vinylheterocycles as Rho-associated coiled-coil kinase (ROCK) inhibitors
CN111741754A (zh) 2017-10-30 2020-10-02 凯莫森特里克斯股份有限公司 作为免疫调节剂的氘代化合物
CN113164403A (zh) 2018-11-30 2021-07-23 凯莫森特里克斯股份有限公司 胶囊制剂
CN116322775A (zh) 2020-06-02 2023-06-23 阿雷斯贸易股份有限公司 IgA肾病治疗的相关方法
CN114163380B (zh) * 2021-12-06 2023-11-07 重庆医科大学 阿伐可泮中间体及其制备方法和用途
CN114262291B (zh) * 2022-01-04 2023-05-19 重庆医科大学 一种阿伐可泮的合成方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7622500A (en) 2000-09-29 2002-07-01 Neurogen Corp High affinity small molecule c5a receptor modulators
ITMI20012025A1 (it) 2001-09-28 2003-03-28 Dompe Spa Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono
CA2479928A1 (fr) 2002-03-28 2003-10-09 Neurogen Corporation Biarylamides substitues en tant que modulateurs du recepteur c5a
WO2003082828A1 (fr) 2002-03-28 2003-10-09 Neurogen Corporation Tetrahydroisoquinoleines substituees servant de modulateurs du recepteur c5a
WO2003084524A1 (fr) 2002-03-29 2003-10-16 Neurogen Corporation Therapie combinatoire pour le traitement de maladies faisant intervenir des composants inflammatoires
US7169775B2 (en) 2002-08-21 2007-01-30 Neurogen Corporation Amino methyl imidazoles as C5a receptor modulators
AU2003291403A1 (en) 2002-11-08 2004-06-03 Neurogen Corporation 3-substituted-6-aryl pyridined as ligands of c5a receptors
AU2003902354A0 (en) 2003-05-15 2003-05-29 Harkin, Denis W. Treatment of haemorrhagic shock
US20060154917A1 (en) 2003-07-03 2006-07-13 Neurogen Corporation Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators
JP5819730B2 (ja) * 2008-12-22 2015-11-24 ケモセントリックス，インコーポレイティド Ｃ５ａＲアンタゴニスト
US20110275639A1 (en) * 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
DK2585064T3 (en) * 2010-06-24 2017-07-24 Chemocentryx Inc C5aR antagonists
AU2012212254A1 (en) 2011-01-31 2013-09-19 Royal Medical Group, Pllc Pluripotent stem cells and method of stimulating and extracting non-embryonic pluripotent stem cells from mammal blood and using reconstituted pluripotent stem cells to treat diseases including chronic obstructive pulmonary disease
JP6898229B6 (ja) * 2014-09-29 2021-07-28 ケモセントリックス，インコーポレイティド Ｃ５ａＲアンタゴニスト製造における方法及び中間体
SG11201808625QA (en) * 2016-04-04 2018-10-30 Chemocentryx Inc SOLUBLE C5aR ANTAGONISTS
CN111741754A (zh) 2017-10-30 2020-10-02 凯莫森特里克斯股份有限公司 作为免疫调节剂的氘代化合物

Also Published As

Publication number Publication date
IL273605A (en) 2020-05-31
KR20200109298A (ko) 2020-09-22
EP3703687A1 (fr) 2020-09-09
JP2021501175A (ja) 2021-01-14
TW201922704A (zh) 2019-06-16
AU2018359214A1 (en) 2020-04-16
US20190144389A1 (en) 2019-05-16
WO2019089468A1 (fr) 2019-05-09
CN111741754A (zh) 2020-10-02
EP3703687A4 (fr) 2021-04-07
US20210276955A1 (en) 2021-09-09
CA3077395A1 (fr) 2019-05-09
US11807609B2 (en) 2023-11-07

Similar Documents

Publication Publication Date Title
FR24C1009I2 (fr) Composés utilisés comme inhibiteurs de kinase
MA46045A (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA45669A (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA44860A (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA52119A (fr) Composés hétérocycliques utilisés comme immunomodulateurs
EP3720430A4 (fr) Composés benzocarbonyle
MA45116A (fr) Composés hétérocycliques comme immunomodulateurs
EP3836923A4 (fr) Composés pyrrolo-dipyridine
EP3691623A4 (fr) Composés de benzosulfonyle
MA52948A (fr) Composés
MA55633A (fr) Salicylamides de spiroheptane et composés associés utilisés comme inhibiteurs de rock
MA51669A (fr) Composés
EP4061364A4 (fr) Composés hétéroaryles
MA53003A (fr) Composés
MA42990A (fr) Composés utiles en tant qu'immunomodulateurs
EP3727401A4 (fr) Composés dinucléotidiques cycliques utilisés comme agonistes sting
MA50609A (fr) Énantiomères de thiazoles substitués utilisés comme composés antiviraux
MA46373A (fr) Composés utilisés comme modulateurs de ror gamma
MA47420A (fr) Composés inhibiteurs d'oga
EP3728289A4 (fr) Composés optimisés
MA41803A (fr) Dérivés amino-indazoles utilisés comme inhibiteurs des canaux sodiques
EP3386952A4 (fr) Composés de benzimidazolium, pyrido-imidazolium ou pyrazino-imidazolium substitués utilisés comme agents chimiothérapeutiques
EP3464336A4 (fr) Composés
EP3374428A4 (fr) Composés soufrés utilisés comme solvants
MA52946A (fr) Composés